Optimer shares slide after it halts trial; Theratechnologies shares surge on Egrifta approval;

 @FierceBiotech: GSK: Expect more M&A deals and new collaborative enterprises. News | Follow @FierceBiotech

 @JohnCFierce: Second take on Arena: Looks pretty bleak for any quick OK. The CEO keeps digging deeper and deeper, though. Is his job on the line? Follow @JohnCFierce

> Shares of Optimer slid eight percent on the news that an unexpectedly high rate of skin rashes forced it to shelve a study of its infectious diarrhea therapy. Story

> The FDA has approved Theratechnologies' Egrifta, a new drug to treat abdominal fat in HIV patients, sending its shares up 15 percent this morning. Report

> Watson Pharmaceuticals has decided to shutter its program for Uracyst after the therapy failed a pilot study for interstitial cystitis. Report

> Athersys has won a green light from the FDA for its Phase II study of the adult stem cell treatment MultiStem for ulcerative colitis. MultiStem is already in the clinic for a number of conditions. Story

> Xoma touted some fresh positive results from a tiny study of a new drug for uveitis. Report

And Finally... Investigators at the University of Michigan say they have found a new way to target idiopathic pulmonary fibrosis. Story

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.